1. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. (15th February 2017) Authors: Quach, Hang; Fernyhough, Liam; Henderson, Ross; Corbett, Gillian; Baker, Bart; Browett, Peter; Blacklock, Hilary; Forsyth, Cecily; Underhill, Craig; Cannell, Paul; Trotman, Judith; Neylon, Annette; Harrison, Simon; Link, Emma; Swern, Arlene; Cowan, Linda; Dimopoulos, Meletios A.; Miles Prince, H. Journal: British journal of haematology Issue: Volume 177:Number 3(2017) Page Start: 441 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Electronic FRAIL score may predict treatment outcomes in older adults with myeloma. Issue 4 (May 2021) Authors: Chan, Henry; Chong, Yih Harng; Seow, Min Yee; Li, Jian; Garg, Priya; Kelly, Meaghan; Neylon, Annette; McDiarmid, Bridgett; Tan, Sarah; Jackson, Sharon Journal: Journal of geriatric oncology Issue: Volume 12:Issue 4(2021) Page Start: 515 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗